Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension

Mineralys Therapeutics' Phase 3 Launch-HTN trial, involving over 1,000 participants with uncontrolled hypertension, demonstrated that lorundrostat (50mg daily) significantly reduced systolic blood pressure, achieving a 16.9 mmHg decrease at Week 6 and a 19.0 mmHg decrease at Week 12, with a favorable safety profile. These results, presented at the European Meeting on Hypertension, support lorundrostat's potential as an effective treatment for patients with uncontrolled hypertension, and the company is pursuing regulatory approval based on these and prior trial results.

Analysis

Mineralys Therapeutics (MLYS) reported positive results from its pivotal Phase 3 Launch-HTN trial for lorundrostat, an aldosterone synthase inhibitor, in over 1,000 participants with uncontrolled or resistant hypertension. The 50mg once-daily dose achieved a statistically significant 16.9 mmHg absolute reduction in systolic blood pressure at Week 6 (-9.1 mmHg placebo-adjusted, p < 0.0001) and a 19.0 mmHg reduction at Week 12 (-11.7 mmHg placebo-adjusted, p < 0.0001), alongside a favorable safety and tolerability profile with modest, reversible effects on serum electrolytes and no observed cortisol suppression. These findings, from the largest hypertension trial of an aldosterone synthase inhibitor and complementing the previously reported positive Advance-HTN trial, strengthen lorundrostat's potential for addressing a significant unmet need in hypertension driven by dysregulated aldosterone, potentially supporting future regulatory submissions. However, the company's outlook carries inherent risks associated with clinical-stage biopharmaceuticals, including the preliminary nature of some analyses, ultimate FDA approval uncertainty, and heavy reliance on lorundrostat's success. Insider trading activity over the past six months reveals substantial purchases by large shareholders and affiliated entities, totaling approximately $37.2 million, while key executives (CMO, CEO, CFO) collectively sold shares worth around $1.8 million. Hedge fund activity indicates net positive institutional interest, with 104 investors adding MLYS shares versus 49 decreasing positions in the most recent quarter, highlighted by significant new stakes from firms like Suvretta Capital Management ($26.5M) and Integral Health Asset Management ($22.6M), although notable exits such as OrbiMed Advisors ($25.6M) were also observed. Analyst sentiment is currently constructive, with two "Buy" ratings from Guggenheim and H.C. Wainwright and a median price target of $45.0.

Key Decisions for Investors

• The strong Phase 3 Launch-HTN trial results for lorundrostat, demonstrating clinically meaningful blood pressure reduction and a favorable safety profile, bolster the investment case for Mineralys Therapeutics, although the single-product focus necessitates careful risk assessment.
• Investors should closely monitor upcoming catalysts, including further detailed data analyses from the Launch-HTN trial, progress towards an NDA submission to the FDA, and any communications regarding long-term efficacy and safety.
• While substantial insider purchases by major shareholders are a positive signal, the concurrent sales by top executives and mixed major movements in hedge fund holdings (though net institutional additions are positive) warrant consideration in evaluating overall market conviction and risk.
• With analysts setting a median price target of $45.0, investors should assess the current share price relative to this target and the company's developmental stage, factoring in both the significant market opportunity for lorundrostat and the inherent biotech regulatory hurdles.